Drugs /

ketorolac

Back to Drugs List

Overview

NCI Definition [1]:
A synthetic pyrrolizine carboxylic acid derivative with anti-inflammatory, analgesic, and antipyretic activities. Ketorolac non-selective inhibits the enzymes cyclooxygenase 1 (COX-1) and COX-2. The inhibition of COX-2, up-regulated at sites of inflammation, prevents conversion of arachidonic acid to pro-inflammatory prostaglandins. The inhibition of COX-1 by this agent prevents the normal steady-state production of prostaglandins that play housekeeping roles in the protection of the gastrointestinal tract, the regulation of renal blood flow, and platelet aggregation. As a result, the inhibition of COX-1 may be associated with gastrointestinal toxicity, nephrotoxicity, and the inhibition of platelet aggregation.

Clinical Trials

View Clinical Trials for ketorolac

Ketorolac has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating ketorolac, 1 is early phase 1 (1 open).

Non-small cell lung carcinoma and renal cell carcinoma are the most common diseases being investigated in ketorolac clinical trials [2].

Drug Details

Synonyms [2]:
ketorolac, (+-)-ketorolac, ketorolac, ketorolac (product), ketorolac [chemical/ingredient], 1h-pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro, rac-ketorolac, (+-)-5-benzoyl-2,3-dihydro-1h-pyrrolizine-1-carboxylic acid, ketorolaco, 74103-06-3 (racemic), 66635-83-4, ketorolac (substance), ketorolacum, kétorolac
NCIT ID [1]:
C1219
SNOMED ID [1]:
F-614DD

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.